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Abstract
Enterobacteriaceae producing carbapenemases, such as KPC or metallo-b-lactamases (MBLs), have emerged on several continents. Pheno-
typic tests are urgently needed for their rapid and accurate detection. A novel carbapenemase detection test, comprising a meropenem
disk, and meropenem disks supplemented with 730 lg of EDTA, 1000 lg of dipicolinic acid (DPA), 600 lg of aminophenylboronic acid
(APBA), or 750 lg of cloxacillin, was evaluated against Klebsiella pneumoniae isolates with KPC (n = 34), VIM (n = 21), IMP (n = 4) or
OXA-48 (n = 9) carbapenemases, and carbapenem-resistant Enterobacteriaceae with porin loss in combination with an extended-spec-
trum b-lactamase (ESBL) (n = 9) or AmpC hyperproduction (n = 5). Commercially available diagnostics tablets from Rosco containing
meropenem and the same inhibitors as described above (except EDTA) were also evaluated. An increased meropenem inhibition zone
was sought in the presence of each added b-lactamase inhibitor. APBA had excellent sensitivity for detecting K. pneumoniae with KPC
enzymes. Isolates with combined AmpC hyperproduction and porin loss were also positive in the APBA test but, unlike KPC producers,
showed cloxacillin synergy. Both DPA and EDTA had excellent sensitivity for detection of MBL-producing K. pneumoniae. However,
EDTA showed poor speciﬁcity, with positive results noted for 1/9 ESBL-producing isolates, for 4/34 KPC-producing isolates, and for
4/9 OXA-48-producing isolates, whereas all of these were negative when DPA was used. The in-house test distinguished accurately
between several different mechanisms mediating reduced susceptibility to carbapenems in Enterobacteriaceae. The commercial combi-
nation tablets from Rosco performed similarly to the in-house test, with the exception of one false-positive MBL result and one false-
positive KPC result among the OXA-48 producers.
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Introduction
The rapid international spread of Klebsiella pneumoniae strains
that produce KPC class A carbapenemases, recently also
classiﬁed as extended-spectrum b-lactamase (ESBL)CARBA-A
[1], is a major concern. Treatment options are severely lim-
ited, owing to linked multiresistance, and the association of
both KPC-2 and KPC-3 with the successful ST258 K. pneu-
moniae clone [2] is a great challenge for infection control.
Several tests have been described for phenotypic detection
of KPC b-lactamases. A modiﬁed version of the cloverleaf
(Hodge) test, originally established for detection of penicillin-
ases [3], accurately detects KPC b-lactamases [4], but is not
able to discriminate between these and other carbapenemas-
es. Moreover, performance of this test requires experience,
as the interpretation may not be straightforward with all
carbapenemase-producing Enterobacteriaceae (A. Vatopoulos,
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personal communication). Recently, a boronic acid disk test
for the detection of KPC-producing K. pneumoniae was
described [5], but it was not evaluated against Enterobacteria-
ceae with carbapenem resistance arising from a combination
of porin loss and hyperproduction of chromosomal AmpC/
plasmid-mediated AmpC, which might also be predicted to
give positive results. Thus, the speciﬁcity of this test has not
been fully evaluated.
Moreover, the emergence of metallo-b-lactamases (MBLs)
in K. pneumoniae [6] and other Enterobacteriaceae, and their
predominance among carbapenemase producers in, for exam-
ple, Greece, has created a need for a reliable phenotypic test
that can detect and distinguish clinically important carbapene-
mases. The rapid emergence of KPC-producing Enterobacteria-
ceae on several continents [7] emphasizes that such an assay is
urgently needed from an infection control perspective.
The aim of this study was to determine whether merope-
nem disks supplemented with four b-lactamase inhibitors
(dipicolinic acid (DPA), EDTA, aminophenylboronic acid
(APBA) or cloxacillin) would be able to discriminate between
various carbapenemase-producing Enterobacteriaceae, and
carbapenem-non-susceptible isolates with ESBL/AmpC hyper-
production in combination with porin changes. Also, we eval-
uated the performance of commercially available diagnostic
tablets containing meropenem in combination with DPA,
APBA and cloxacillin.
Materials and Methods
Bacterial isolates
Well-characterized strains from several countries producing
various b-lactamases were included in this study. The panel
consisted of clinical isolates of KPC-2-producing (n = 9) and
KPC-3-producing (n = 12) K. pneumoniae from the CDC [8],
KPC-producing ST258 K. pneumoniae from the Health Pro-
tection Agency (HPA), London (n = 6) [9], and KPC-2-pro-
ducing (n = 6) and KPC-3-producing (n = 1) ST258
K. pneumoniae from Norway and Sweden [2]. Isolates of
VIM-1-producing K. pneumoniae from Greece (n = 12), VIM-
1-producing K. pneumoniae from Norway and Sweden
(n = 6), VIM-1-producing (n = 3) and IMP-producing (n = 3)
K. pneumoniae and Escherichia coli (n = 1) from the HPA rep-
resented MBL-producing Enterobacteriaceae. K. pneumoniae
isolates producing OXA-48 carbapenemase were obtained
from the HPA (n = 9) (Zhang, 19th ECCMID, 2009, Abstract
L249). Carbapenem-resistant K. pneumoniae isolates with
CTX-M-15-type and/or SHV-type ESBLs in combination with
loss of porins OmpK35 and/or OmpK36 (n = 9), as well as
Enterobacter cloacae and Enterobacter aerogenes isolates hyper-
producing AmpC and with complete or partial loss of OmpF
and/or OmpC (n = 5) [10], were included to investigate the
speciﬁcity of the various tests. Finally, three isolates of E. coli
and one isolate of Enterobacter cloacae with a combination of
plasmid-mediated (CMY-2) or chromosomal AmpC, ESBLs
(CTX-M-15 or SHV-12) and porin loss were included.
Preparation of combination disks
Meropenem disks (Oxoid, Basingstoke, UK) were supple-
mented with 10 lL of three different b-lactamase inhibitors:
100 mg/mL DPA (Sigma, St Louis, MO, USA) (modiﬁed from
Kimura et al.) [11], 0.2 M EDTA (Sigma) [12], 60 mg/mL
APBA (Sigma) and 75 mg/mL cloxacillin (Sigma). Hence, the
ﬁnal amounts of b-lactamase inhibitor in the disks were
1000 lg of DPA, 730 lg of EDTA, 600 lg of APBA and
750 lg of cloxacillin. DPA was dissolved in dimethylsulphox-
ide (Sigma), whereas EDTA, APBA and cloxacillin were dis-
solved in sterile water. Disks were left to dry at room
temperature for 30 min before they were used.
Test procedure and interpretation of the combination disk
assay
A 0.5 McFarland inoculum was prepared and spread on cat-
ion-adjusted Mueller–Hinton II agar plates (Becton-Dickinson,
Cockeysville, MD, USA). Five disks were placed on each
plate: meropenem 10 lg, meropenem 10 lg + DPA, me-
ropenem 10 lg + EDTA, meropenem 10 lg + APBA and
meropenem 10 lg + cloxacillin. An increase ‡5 mm in zone
diameter around disks containing b-lactamase inhibitors, as
compared with the disk with meropenem alone, was consid-
ered to be a positive result for DPA, EDTA and cloxacillin,
whereas an increase ‡ 4 mm was considered to be a positive
result for APBA. An increase ‡4 mm for APBA was selected
because 4/34 KPC-producing K. pneumoniae isolates only had
an increase of 4 mm and were thus not detected with a cut-
off ‡5 mm.
Commercial diagnostic tablets from Rosco (Rosco Diag-
nostica A/S, Taastrup, Denmark) were evaluated against the
same isolates. Four tablets were placed on each plate: me-
ropenem, meropenem + DPA, meropenem + APBA and me-
ropenem + cloxacillin. The procedure was identical to the
one used for applying in-house disks. An increase ‡5 mm in
zone diameter around tablets containing b-lactamase inhibi-
tors, as compared with the tablet with meropenem alone,
was considered a positive result, according to the manufac-
turer’s instruction.
Modiﬁed cloverleaf (Hodge) test)
The modiﬁed cloverleaf test was performed according to
Anderson et al. [4]. In brief, cation-adjusted Mueller-Hinton II
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agar plates (Becton-Dickinson) were inoculated with a 1 : 10
dilution of a 0.5 McFarland suspension of E. coli ATCC 25922
and streaked for conﬂuent growth with a swab. A 10-lg im-
ipenem disk (Oxoid) was placed in the centre, and each test
isolate was streaked from the disk to the edge of the plate.
The presence of a distorted inhibition zone after overnight
incubation was interpreted as a positive result.
Sensitivity and speciﬁcity
The performance of the various disks for detection of differ-
ent b-lactamases was determined with genotypically deﬁned
carbapenem resistance mechanisms as the reference stan-
dard. For each test and category of b-lactamase, sensitivity
was calculated from the number of true-positive bacteria,
whereas speciﬁcity was calculated from the number of true-
negative bacteria.
Results and Discussion
The results are displayed in Table 1. Synergy with EDTA was
observed in all 25 MBL producers, but also in 4/34 isolates
of KPC-producing K. pneumoniae, in 1/9 isolates of K. pneu-
moniae with CTX-M-15 and porin loss, and in 4/9 isolates of
OXA-48-producing K. pneumoniae. An association between
OXA carbapenemase production and a false-positive EDTA
test result has been described previously [13], but not for
the OXA-48 enzyme. In comparison, all MBL producers
were detected with disks containing DPA, and no isolates
featuring other mechanisms of resistance displayed any syn-
ergy with DPA (Table 1).
APBA synergy detected all isolates of KPC-producing
K. pneumoniae. Many isolates with a combination of AmpC
hyperproduction and porin loss were also positive in the
APBA test, but these isolates additionally showed cloxacillin
synergy, in contrast to the isolates with KPC enzymes. One
OXA-48-producing K. pneumoniae isolate was positive in the
APBA test, but not with cloxacillin. None of the other iso-
lates in this strain collection was positive with APBA or clox-
acillin. In summary, the sensitivity of the APBA test for
detection of KPC was 100%, and the speciﬁcity was 98% if
the additional criterion of a negative cloxacillin result was
included (Table 2).
The commercial tablets from Rosco performed almost as
well as the in-house disks for detection of MBL and KPC
b-lactamase (Table 3). The sensitivity was 100% in both cases,
whereas one false-positive OXA-48-producing isolate was
detected both with tablets containing DPA and with tablets
containing APBA. The tablet containing cloxacillin identiﬁed
only 2/5 isolates with combined AmpC hyperproduction and T
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porin loss. More importantly, these two isolates were also
the only ones that were positive with the tablet containing
APBA, for which reason none of them was misidentiﬁed as a
KPC-producing isolate.
The modiﬁed cloverleaf test has been suggested as a use-
ful method for detecting carbapenemases in Enterobacteria-
ceae. In our study, the sensitivity of this method was
excellent, but the speciﬁcity was only 78%, the reason being
that four isolates with the combination of AmpC hyperpro-
duction and porin loss were positive. It should be noted that
all of these isolates were Enterobacter spp., and the question
of false-positive reactions in other species of Enterobacteria-
ceae, including those with acquired AmpC variants, remains
unanswered. Furthermore, the subjective character of the
test may cause problems of interpretation in laboratories
lacking experience or with few carbapenem-resistant Entero-
bacteriaceae. Recently, Pasteran et al. and Carvalhaes et al.
[14,15] have both reported similar ﬁndings, with poor speci-
ﬁcity of the modiﬁed cloverleaf test. As a consequence of
the poor performance of the test, Pasteran et al. [14] sug-
gested yet another modiﬁcation of the test. In the last modi-
ﬁcation of the cloverleaf test, inhibitors are added to the
disk placed in the centre of the agar plate.
One limitation of the study is the large proportion of
ST258 KPC-producing isolates, as other clones may theoreti-
cally be more difﬁcult to detect with these methods. A cer-
tain level of clonal diversity was observed between the KPC
producers [8], and strains that were not K. pneumoniae
ST258 responded equally well to the applied b-lactamase
inhibitors. Also, the recent emergence in Greece of K. pneu-
moniae isolates featuring both VIM and KPC b-lactamases
simultaneously [16] poses another challenge to this protocol.
Probably, such isolates can be identiﬁed with addition of
both DPA and APBA to meropenem disks, but owing to the
lack of control isolates with this mechanism of resistance,
this remains speculative.
In conclusion, synergy with APBA and cloxacillin was seen
in isolates with porin loss and hyperproduction of AmpC,
whereas synergy with APBA only had excellent speciﬁcity for
KPC-producing isolates (Figure 1). DPA had excellent sensi-
tivity and speciﬁcity for the detection of MBL-producing
K. pneumoniae, whereas the poor speciﬁcity of EDTA ques-
tions the usefulness of this inhibitor. OXA-48-producing
K. pneumoniae may become positive both in the DPA and in
the APBA assay. It should also be noted that concomitant
production of OXA-48 and the novel MBL NDM-1 has now
been described (Karthikeyan et al., 20th ECCMID, 2010,
Abstract P742), and such isolates will most probably be posi-
tive in the DPA assay. OXA-48 production should be consid-
ered for isolates that cannot be conﬁrmed to produce a
class A or class B carbapenemase, and investigated by PCR
of blaOXA-48 in such cases.
The main advantages of this novel assay over the modiﬁed
cloverleaf test are the more objective analysis and the possibil-
ity of discriminating between various classes of carbapenemas-
es. The addition of cloxacillin enabled discrimination between
KPC producers and isolates with combined porin loss and
TABLE 2. Sensitivities and speciﬁcities of dipicolinic acid
(DPA), aminophenylboronic acid (APBA), cloxacillin and
the modiﬁed cloverleaf test for detecting various b-lacta-
mases
Test
b-Lactamases
sought by
test(s)
Sensitivity
(%)
Speciﬁcity
(%)
APBA-positive, cloxacillin-negative KPC 100 98
APBA-positive, cloxacillin-positive AmpCa 80 100
EDTA-positive MBL 100 88
DPA-positive MBL 100 100
Positive cloverleaf test result KPC, MBL,
OXA-48
100 78
MBL, metallo-b-lactamase.
aCombination of AmpC hyperproduction and porin loss.
TABLE 3. Sensitivities and speciﬁcities of commercial disks
from Rosco for detecting various b-lactamases
Test
b-Lactamases
sought by
test(s)
Sensitivity
(%)
Speciﬁcity
(%)
APBA-positive, cloxacillin-negative KPC 100 98
APBA-positive, cloxacillin-positive AmpCa 40 100
DPA-positive MBL 100 98
APBA, aminophenylboronic acid; DPA, dipicolinic acid; MBL, metallo-b-lactam-
ase.
aCombination of AmpC hyperproduction and porin loss.
Non-wild type* to 
≥1 carbapenem
in K. pneumoniae
Synergy with APBA 
but not cloxacillin
KPC (or other class
A carbapenemase)
Synergy with APBA
and cloxacillin
AmpC and porin 
loss
Synergy with DPA
only
MBL
FIG. 1. Algorithm for interpretation of results with b-lactamase
inhibitors. APBA, aminophenylboronic acid; DPA, dipicolinic acid;
MBL, metallo-b-lactamase. * MIC above the epidemiological cut-off
values deﬁned by EUCAST (European Committee on Antimicrobial
Susceptibility Testing).
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AmpC hyperproduction. The current data are, perhaps, not in
support of interpretative reading of test results based on the
ﬁnding of a carbapenemase, at least for VIM-producing
K. pneumoniae [17]. However, detection of carbapenemases in
Enterobacteriaceae is still very important from an infection con-
trol and epidemiological point of view, and may impact greatly
on patient management at institutions experiencing increasing
rates of carbapenem resistance in Enterobacteriaceae.
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